|
Jun 13
|
Bavarian Nordic launches chikungunya vaccine trial for paediatric population
|
|
Jun 12
|
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
|
|
May 16
|
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
|
|
Apr 1
|
FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine
|
|
Mar 31
|
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
|
|
Feb 19
|
Undiscovered Gems And 2 Other Promising Small Caps With Strong Potential
|
|
Feb 17
|
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
|
|
Oct 3
|
Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
|
Sep 27
|
UNICEF secures one million mpox vaccines for Africa
|
|
Jul 26
|
Bavarian Nordic wins positive CHMP opinion to amend Imvanex approval
|
|
Jul 26
|
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
|
|
Jun 17
|
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
|
|
Mar 21
|
Bavarian Nordic A/S – Notice Convening Annual General Meeting
|
|
Nov 30
|
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
|
|
Nov 30
|
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
|
|
Aug 6
|
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
|
|
Jun 23
|
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
|
|
Jun 20
|
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
|